Edition:
United Kingdom

Novozymes A/S (NZYMb.CO)

NZYMb.CO on Copenhagen Stock Exchange

323.00DKK
16 May 2019
Change (% chg)

kr.2.00 (+0.62%)
Prev Close
kr.321.00
Open
kr.321.80
Day's High
kr.324.60
Day's Low
kr.319.10
Volume
498,575
Avg. Vol
522,498
52-wk High
kr.363.10
52-wk Low
kr.260.10

Latest Key Developments (Source: Significant Developments)

Novozymes Q1 EBIT At DKK 895 Mln, Below Expectations
Wednesday, 24 Apr 2019 

April 24 (Reuters) - Novozymes A/S ::REG-INTERIM REPORT FOR THE FIRST 3 MONTHS OF 2019.FULL-YEAR EARNINGS OUTLOOK MAINTAINED AFTER EARLY-APRIL UPGRADE.Q1 TOTAL SALES DKK 3.48 BLN; RTRS POLL DKK 3.60 BLN.NARROWED SALES GROWTH GUIDANCE FOLLOWING WEAKNESS IN US BIOETHANOL..Q1 NET PROFIT DOWN 14% Y/Y DUE TO LOWER EBIT AND HEDGING LOSSES.Q1 EBIT DKK 895 MLN; RTRS POLL DKK 1.02 BLN.FLOODS IN THE MIDWEST HAVE MADE IT TOUGHER FOR OUR CUSTOMERS..IT WILL BE DIFFICULT TO REACH THE TOP END OF THE GUIDED ORGANIC SALES GROWTH RANGE, AND WE ADJUST OUR OUTLOOK TO 3-5%..SAYS MIDDLE EAST COMPARISON GETS EASIER.SALES TO THE HOUSEHOLD CARE INDUSTRY DECLINED BY 3% ORGANICALLY AND BY 2% IN DKK IN THE FIRST QUARTER OF 2019 COMPARED WITH THE FIRST QUARTER OF 2018.DEVELOPED MARKETS FLAT; 10% ORGANIC SALES DECLINE IN EMERGING MARKETS, WITH THE MIDDLE EAST AS THE MAIN DRAG.NEGATIVE IMPACT FROM THE MIDDLE EAST, FEED ENZYMES AND THE PLANNED PRICE REDUCTIONS IN US BAKING ENZYMES.FOOD & BEVERAGES SALES DECLINED BY 2% ORGANICALLY AND GREW BY 1% IN DKK IN THE FIRST QUARTER OF 2019 COMPARED WITH THE SAME PERIOD LAST YEAR.Q1 SALES TO BIOENERGY DECLINED BY 8% ORGANICALLY AND BY 4% IN DKK COMPARED WITH THE FIRST QUARTER OF 2018..STOCK BUYBACK PROGRAM OF UP TO DKK 2BN TO BE INITIATED APRIL 25, 2019..  Full Article

Elanco Announces Collaboration Agreement With Novozymes For Nutritional Health Innovation
Friday, 2 Nov 2018 

Nov 2 (Reuters) - Elanco Animal Health Inc ::ELANCO ANNOUNCES COLLABORATION AGREEMENT WITH NOVOZYMES FOR NUTRITIONAL HEALTH INNOVATION.ELANCO ANIMAL HEALTH INC - RESEARCH AND DEVELOPMENT COLLABORATION WITH NOVOZYMES A/S TO DEVELOP NUTRITIONAL HEALTH PRODUCTS FOR BEEF CATTLE AND DAIRY COWS GLOBALLY.ELANCO ANIMAL HEALTH INC - COMPANIES WILL COLLABORATE TO DEVELOP A RESEARCH AND DEVELOPMENT PIPELINE AND COMMERCIALIZE PRODUCTS IN NEXT DECADE..  Full Article

BioAg Alliance Announces Updated Research And Development Pipeline
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - BioAg Alliance::BIOAG ALLIANCE - ANNOUNCED UPDATED RESEARCH AND DEVELOPMENT PIPELINE.BIOAG ALLIANCE - SEES ACCELERON B-300 SAT TO BE APPLIED TO BETWEEN 8-10 MILLION ACRES IN 2018, WHILE ACCELERON B-360 ST SCHEDULED TO ENTER MARKET IN 2019.BIOAG ALLIANCE - IN 2019-2020, PLAN TO LAUNCH PRODUCTS FOR GROWERS OF CORN, OILSEED RAPE AND WHEAT IN EUROPE.  Full Article

Novozymes Appoints Prisca Havranek-Kosicek New CFO
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - NOVOZYMES ::PRISCA HAVRANEK-KOSICEK NEW CFO.  Full Article

Novozymes CEO Sells 50,000 Of Own Shares
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Novozymes ::CEO SELLS 50.000 OF OWN SHARES IN COMPANY FOR A TOTAL VALUE OF DKK 17.2 MILLION.  Full Article

Novozymes completes share buyback program
Friday, 10 Nov 2017 

Nov 10 (Reuters) - NOVOZYMES ::‍NOVOZYMES HAS NOW COMPLETED ANNOUNCED SHARE BUYBACK PROGRAM OF B SHARES WORTH UP TO DKK 2 BILLION IN TOTAL DURING 2017​.  Full Article

Novozymes Q3 EBIT above expectations at DKK 1.06 bln
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - NOVOZYMES ::‍FULL-YEAR OUTLOOK ADJUSTED​.‍NOW EXPECTS ORGANIC REVENUE GROWTH 3-5% (2-5%)​.NOVOZYMES - STILL SOME UNCERTAINTY REGARDING AGRICULTURE-RELATED MARKETS IN Q4‍​.NOW EXPECTS ‍DKK REVENUE GROWTH 2-4% (1-4%)​.NOW EXPECTS ‍EBIT GROWTH 2-4% (1-4%)​.Q3 SALES DKK ‍​3.58 BILLION (REUTERS POLL DKK 3.54 BILLION).Q3 EBIT DKK ‍​1.06 BILLION (REUTERS POLL DKK 1.01 BILLION).Q3 NET PROFIT 819 MILLION (REUTERS POLL DKK 789 MILLION).  Full Article

Novozymes ‍Q2 EBIT at DKK ‍​963 mln, below expectations
Friday, 11 Aug 2017 

Aug 11 (Reuters) - NOVOZYMES ::‍Q2 EBIT MARGIN AT 28.2%, EXCLUDING REORGANIZATION COSTS (Q2 2016: 28.0%)​.Q2 EBIT DKK ‍​963 MILLION (REUTERS POLL DKK 994 MILLION).Q2 NET PROFIT 735 MILLION (REUTERS POLL DKK 764 MILLION).Q2 SALES DKK 3.54 BILLION (REUTERS POLL DKK 3.58 BILLION).MAINTAINS ITS FULL-YEAR ORGANIC SALES GROWTH OUTLOOK OF 2-5%‍​.CONTINUES TO EXPECT HIGHER H2 Y/Y ORGANIC GROWTH RELATIVE TO THE 3% DELIVERED IN H1 Y/Y.UNDERLYING EBIT GROWTH OUTLOOK FOR THE FULL YEAR IS MAINTAINED.  Full Article

Novozymes CFO steps down
Thursday, 15 Jun 2017 

June 15 (Reuters) - NOVOZYMES ::BENNY D. LOFT TO STEP DOWN AS CFO AND EXECUTIVE VICE PRESIDENT.  Full Article

Photo

Novozymes sees lower sales due to weak, flood-hit ethanol market

COPENHAGEN Danish enzymes maker Novozymes lowered its 2019 sales outlook on Wednesday after its bioenergy business was hit by weaker-than-expected U.S. ethanol production following floods in the Midwest.